Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lens
Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens.
Designed to mimic the natural focusing ability of the youthful human eye, the Ocumetics Lens aims to provide patients with seamless, dynamic vision across a full range of distances following cataract surgery. The clinical trial will assess the lens’s safety, effectiveness, and ability to restore near and distance vision.
“This moment is nothing short of transformational,” Dean Burns, CEO of Ocumetics, said in a company news release. “What began as a dream to restore the eye’s natural ability to focus—eliminating the need for glasses or contact lenses—is now on the cusp of clinical reality.”
Key Developments Ahead of Clinical Trials
Ocumetics has achieved a series of critical milestones in preparation for this summer’s FIH study:
Lens Design Finalized: The lens design has undergone a “design freeze,” signaling the transition from R&D to commercial-readiness
Manufacturing Milestone: The first clinical-grade batch of Ocumetics Lenses has been successfully manufactured and validated for implantation
Bench Testing Success: Laboratory evaluations have confirmed the lens’s accommodative power, demonstrating its ability to restore functional vision without glasses
Mexico City Chosen as Launch Site: Mexico City was selected as the first clinical site following a thorough evaluation
Clinical Protocol Submitted: The clinical protocol has been finalized and submitted to appropriate regulatory bodies
Funding Secured: Ocumetics has announced a private placement of up to $2.1 million CAD, led by Numus Capital, to support the FIH study and ongoing innovation
According to Ocumetics, the results of the Mexico-based FIH study will pave the way for future global regulatory submissions and potential commercialization.